# Funding Proposal: Series Seed

## The Ask

**$3.0 Million** on a SAFE (Simple Agreement for Future Equity).

## Use of Funds (18 Month Runway)

### 1. R&D Team (45% - $1.35M)

- **Hire 2x ML Researchers**: PhDs in Geometric Deep Learning.
- **Hire 1x Bioinformatics Lead**: To bridge the gap with pharma partners.
- **Hire 1x Full Stack Engineer**: To harden the Enterprise API / Docker containers.

### 2. Wet Lab Validation (30% - $900k)

- **Contract Research Organization (CRO)**: Synthesize top 100 P53 variants and test in-vitro.
- **Viral Pseudotype Assays**: Validate the Omicron escape predictions against live virus neutralization panels.

### 3. Compute & Infrastructure (15% - $450k)

- **Training Cluster**: Reserved A100 instances for training "Foundation Model v2" (All Viral Families).
- **Data Licensing**: Access to proprietary clinical datasets.

### 4. Operations & IP (10% - $300k)

- **Legal**: Patent filings (global).
- **BD/Sales**: Conference attendance (BioJP M, NeurIPS) to source pilot partners.

## Milestones (The "Value Inflection Points")

- **Month 6**: "Foundation Model v2" released (trained on 100M sequences).
- **Month 9**: First wet-lab confirmation of a "Synthetic P53" variant.
- **Month 12**: Signed "Pilot Agreement" with Top-20 Pharma ($500k value).
- **Month 18**: Series A raise at $20M-$40M valuation.
